Progression-free survival and recurrence results for AGITG DOCTOR: Pre-op cisplatin, 5FU & DOCetaxel +/-radiotherapy after poor early response to cisplatin & 5FU for resectable oesophageal adenocarcinoma

A. P. Barbour; E. T. Walpole; G. T. Mai; L. Barnes; D. I. Watson; S. P. Ackland; V. Wills; J. Martin; M. Burge; C. S. Karapetis; J. Shannon; L. M. Nott; V. Gebski; M. Oostendorp; K. Wilson; J. Thomas; G. Lampe; J. R. Zalcberg; J. Simes; M. Smithers

doi:10.1093/annonc/mdy282.003

Progression-free survival and recurrence results for AGITG DOCTOR: Pre-op cisplatin, 5FU & DOCetaxel +/-radiotherapy after poor early response to cisplatin & 5FU for resectable oesophageal adenocarcinoma

A. P. Barbour, E. T. Walpole, G. T. Mai, L. Barnes, D. I. Watson, S. P. Ackland, V. Wills, J. Martin, M. Burge, C. S. Karapetis, J. Shannon, L. M. Nott, V. Gebski, M. Oostendorp, K. Wilson, J. Thomas, G. Lampe, J. R. Zalcberg, J. Simes, M. Smithers

Research output: Contribution to journal › Article › peer-review

Abstract

Resectable oesophageal and gastro-oesophageal junction adenocarci-noma patients (pts) without early metabolic response (EMR) to chemotherapy asdefined by 18-FDG-PET (PET) show poor survival and major histological responserates (RR)<5%. This multicentre trial previously reported changing neoadjuvant ther-apy improved major histological RR for early metabolic non-responders (MNR).Grade 3/4 toxicities were seen in 27% of pts on 5-FUþcisplatin (CF); 42% on doce-taxelþCF (DCF) and 71% on DCFþconcurrent 45Gy radiotherapy (DCFRT).Updated results now report progression-free survival (PFS) and local recurrence.

Original language	English
Pages (from-to)	viii206-viii207
Number of pages	2
Journal	Annals of Oncology : Official Journal of the European Society for Medical Oncology
Volume	29
Issue number	Supp 8
DOIs	https://doi.org/10.1093/annonc/mdy282.003
Publication status	Published - 1 Oct 2018

Access to Document

10.1093/annonc/mdy282.003Licence: In Copyright

Cite this

Barbour, A. P., Walpole, E. T., Mai, G. T., Barnes, L., Watson, D. I., Ackland, S. P., Wills, V., Martin, J., Burge, M., Karapetis, C. S., Shannon, J., Nott, L. M., Gebski, V., Oostendorp, M., Wilson, K., Thomas, J., Lampe, G., Zalcberg, J. R., Simes, J., & Smithers, M. (2018). Progression-free survival and recurrence results for AGITG DOCTOR: Pre-op cisplatin, 5FU & DOCetaxel +/-radiotherapy after poor early response to cisplatin & 5FU for resectable oesophageal adenocarcinoma. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 29(Supp 8), viii206-viii207. https://doi.org/10.1093/annonc/mdy282.003

Barbour, A. P. ; Walpole, E. T. ; Mai, G. T. et al. / Progression-free survival and recurrence results for AGITG DOCTOR : Pre-op cisplatin, 5FU & DOCetaxel +/-radiotherapy after poor early response to cisplatin & 5FU for resectable oesophageal adenocarcinoma. In: Annals of Oncology : Official Journal of the European Society for Medical Oncology. 2018 ; Vol. 29, No. Supp 8. pp. viii206-viii207.

@article{390e1adf8d0940f794b39fee0d6124e2,

title = "Progression-free survival and recurrence results for AGITG DOCTOR: Pre-op cisplatin, 5FU & DOCetaxel +/-radiotherapy after poor early response to cisplatin & 5FU for resectable oesophageal adenocarcinoma",

abstract = "Resectable oesophageal and gastro-oesophageal junction adenocarci-noma patients (pts) without early metabolic response (EMR) to chemotherapy asdefined by 18-FDG-PET (PET) show poor survival and major histological responserates (RR)<5%. This multicentre trial previously reported changing neoadjuvant ther-apy improved major histological RR for early metabolic non-responders (MNR).Grade 3/4 toxicities were seen in 27% of pts on 5-FU{\th}cisplatin (CF); 42% on doce-taxel{\th}CF (DCF) and 71% on DCF{\th}concurrent 45Gy radiotherapy (DCFRT).Updated results now report progression-free survival (PFS) and local recurrence.",

author = "Barbour, {A. P.} and Walpole, {E. T.} and Mai, {G. T.} and L. Barnes and Watson, {D. I.} and Ackland, {S. P.} and V. Wills and J. Martin and M. Burge and Karapetis, {C. S.} and J. Shannon and Nott, {L. M.} and V. Gebski and M. Oostendorp and K. Wilson and J. Thomas and G. Lampe and Zalcberg, {J. R.} and J. Simes and M. Smithers",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy282.003",

language = "English",

volume = "29",

pages = "viii206--viii207",

journal = "Annals of Oncology : Official Journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Elsevier BV",

number = "Supp 8",

}

Barbour, AP, Walpole, ET, Mai, GT, Barnes, L, Watson, DI, Ackland, SP, Wills, V, Martin, J, Burge, M, Karapetis, CS, Shannon, J, Nott, LM, Gebski, V, Oostendorp, M, Wilson, K, Thomas, J, Lampe, G, Zalcberg, JR, Simes, J & Smithers, M 2018, 'Progression-free survival and recurrence results for AGITG DOCTOR: Pre-op cisplatin, 5FU & DOCetaxel +/-radiotherapy after poor early response to cisplatin & 5FU for resectable oesophageal adenocarcinoma', Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 29, no. Supp 8, pp. viii206-viii207. https://doi.org/10.1093/annonc/mdy282.003

Progression-free survival and recurrence results for AGITG DOCTOR: Pre-op cisplatin, 5FU & DOCetaxel +/-radiotherapy after poor early response to cisplatin & 5FU for resectable oesophageal adenocarcinoma. / Barbour, A. P.; Walpole, E. T.; Mai, G. T. et al.
In: Annals of Oncology : Official Journal of the European Society for Medical Oncology, Vol. 29, No. Supp 8, 01.10.2018, p. viii206-viii207.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Progression-free survival and recurrence results for AGITG DOCTOR

T2 - Pre-op cisplatin, 5FU & DOCetaxel +/-radiotherapy after poor early response to cisplatin & 5FU for resectable oesophageal adenocarcinoma

AU - Barbour, A. P.

AU - Walpole, E. T.

AU - Mai, G. T.

AU - Barnes, L.

AU - Watson, D. I.

AU - Ackland, S. P.

AU - Wills, V.

AU - Martin, J.

AU - Burge, M.

AU - Karapetis, C. S.

AU - Shannon, J.

AU - Nott, L. M.

AU - Gebski, V.

AU - Oostendorp, M.

AU - Wilson, K.

AU - Thomas, J.

AU - Lampe, G.

AU - Zalcberg, J. R.

AU - Simes, J.

AU - Smithers, M.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Resectable oesophageal and gastro-oesophageal junction adenocarci-noma patients (pts) without early metabolic response (EMR) to chemotherapy asdefined by 18-FDG-PET (PET) show poor survival and major histological responserates (RR)<5%. This multicentre trial previously reported changing neoadjuvant ther-apy improved major histological RR for early metabolic non-responders (MNR).Grade 3/4 toxicities were seen in 27% of pts on 5-FUþcisplatin (CF); 42% on doce-taxelþCF (DCF) and 71% on DCFþconcurrent 45Gy radiotherapy (DCFRT).Updated results now report progression-free survival (PFS) and local recurrence.

AB - Resectable oesophageal and gastro-oesophageal junction adenocarci-noma patients (pts) without early metabolic response (EMR) to chemotherapy asdefined by 18-FDG-PET (PET) show poor survival and major histological responserates (RR)<5%. This multicentre trial previously reported changing neoadjuvant ther-apy improved major histological RR for early metabolic non-responders (MNR).Grade 3/4 toxicities were seen in 27% of pts on 5-FUþcisplatin (CF); 42% on doce-taxelþCF (DCF) and 71% on DCFþconcurrent 45Gy radiotherapy (DCFRT).Updated results now report progression-free survival (PFS) and local recurrence.

UR - http://www.scopus.com/inward/record.url?scp=85081529205&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy282.003

DO - 10.1093/annonc/mdy282.003

M3 - Article

C2 - 32136430

SN - 0923-7534

VL - 29

SP - viii206-viii207

JO - Annals of Oncology : Official Journal of the European Society for Medical Oncology

JF - Annals of Oncology : Official Journal of the European Society for Medical Oncology

IS - Supp 8

ER -

Barbour AP, Walpole ET, Mai GT, Barnes L, Watson DI, Ackland SP et al. Progression-free survival and recurrence results for AGITG DOCTOR: Pre-op cisplatin, 5FU & DOCetaxel +/-radiotherapy after poor early response to cisplatin & 5FU for resectable oesophageal adenocarcinoma. Annals of Oncology : Official Journal of the European Society for Medical Oncology. 2018 Oct 1;29(Supp 8):viii206-viii207. doi: 10.1093/annonc/mdy282.003

Progression-free survival and recurrence results for AGITG DOCTOR: Pre-op cisplatin, 5FU & DOCetaxel +/-radiotherapy after poor early response to cisplatin & 5FU for resectable oesophageal adenocarcinoma

Abstract

Access to Document

Other files and links

Fingerprint

Cite this